Preventing RSV in Babies: A Scientific Milestone

• 2023

  Sign in to bookmark this resource.

  Sign in
• Paul Offit

---

Access Resources

• LectureEN

About

This 3-minute video discusses the use of nirsevimab (Beyfortus™) to protect vulnerable infants from RSV. Dr. Paul Offit explains its benefits, clinical trial results, and eligibility criteria. Nirsevimab is not a vaccine but an antibody that helps protect against RSV for at least five months. It is recommended for all babies under 8 months before the RSV season and high-risk children aged 8 to 19 months. The drug aims to reduce hospital visits during winter when RSV cases are high.

---

Tags

Focus Area: Infectious Disease

Audiences: Families & Children; Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Nirsevimab Library

Keywords: Bronchiolitis, Viral; Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; Antibodies, Monoclonal, Humanized

Institutions: Children's Hospital of Philadelphia

---

More like this

Vaccine Education Center None · Children's Hospital of Philadelphia Disparities in the Availability and Acceptance of Nirsevimab in Massachusetts 2024 · Harvard Medical School, Boston Children's Hospital Nirsevimab: Alleviating the Burden Of RSV Morbidity in Young Children 2024 · Duke-NUS Medical School, KK Women's & Children's Hospital, University of New South Wales, Macquarie University, National Centre for Immunisation Research and Surveillance (NCIRS)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---